InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (3 ops.)
Insider track record
CFODisclosed buys
0
Disclosed sells
3
T+90 hit rate
47%
T+90 mean return
+2.9%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Korenberg Matthew E, Chief Financial Officer. Insider active across 2 companies, notably Ligand Pharmaceuticals INC. Cumulatively, 26 filings have been logged. Breakdown: 0 buy · 3 sells. Total volume traded: €2m. History available since 30 June 2021. The latest transaction was disclosed on 20 September 2024 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations26 total
4,982 shares@ US$49.995.9% of flowCommon StockSEC:0002001011-24-000087:0
914 shares@ US$55.751.2% of flowCommon StockSEC:0002001011-24-000082:0
1,157 shares@ US$105.542.9% of flowCommon StockSEC:0002001011-24-000078:0
24,554 sharesCommon StockSEC:0001628280-24-038088:0
18,245 shares@ US$98.5043.3% of flowCommon StockSEC:0002001011-24-000071:0
350 shares@ US$60.7070.5% of flowCommon StockSEC:0002001011-24-000064:0
3,440 shares@ US$84.54317.1% of flowCommon StockSEC:0002001011-24-000052:0
14,416 shares0Common StockSEC:0002001011-24-000029:0
4,778 shares@ US$74.658.7% of flowCommon StockSEC:0002001011-24-000018:0
2,917 shares@ US$72.315.0% of flowCommon StockSEC:0002001011-24-000009:0
1,984 shares@ US$59.612.9% of flowCommon StockSEC:0002001011-23-000003:0
376 shares@ US$56.780.5% of flowCommon StockSEC:0000886163-23-000045:0
9,069 shares0Common StockSEC:0000899243-23-006297:0
2,890 shares@ US$72.985.2% of flowCommon StockSEC:0000899243-23-005552:0
3,859 shares@ US$66.296.3% of flowCommon StockSEC:0000899243-22-039583:0
14,000 shares0Common StockSEC:0000899243-22-038699:0
3,593 shares@ US$72.906.7% of flowCommon StockSEC:0000899243-22-037330:0
27,714 shares0Common StockSEC:0000899243-22-035047:0
●
164 shares@ US$75.8370.3% of flowCommon StockSEC:0000886163-22-000107:0
8,062 shares0Common StockSEC:0000886163-22-000090:0
●
906 shares@ US$123.680.0027% mcap73.5% of flowCommon StockSEC:0000886163-22-000021:0
4,803 shares0Common StockSEC:0000886163-22-000014:0
4,803 shares0Common StockSEC:0000886163-22-000014
●
247 shares@ US$85.90950.5% of flowCommon StockSEC:0000886163-21-000097
●
247 shares@ US$85.90950.0005% mcap13.3% of flowCommon StockSEC:0000886163-21-000097:0
25 of 26 declarations
About Korenberg Matthew E
Matthew E. Korenberg is the Chief Financial Officer and Executive Vice President of Ligand Pharmaceuticals Inc. In this role, he is responsible for the company's financial management, including financial planning and analysis. With a strong background in the pharmaceutical sector, he plays a key role in decision-making that impacts Ligand's performance and growth. His expertise is essential for the company's financial success.
